Profectus Biosciences Inc., of Baltimore, said its Genevax IL-12 pDNA adjuvant has significantly improved the vaccine-induced response rate in a Phase I study with 48 healthy volunteers of an experimental DNA vaccine for HIV. The data were presented in Seattle at the annual HIV Vaccine Trials Network Conference held in November.